生物技术公司Vericel Corporation(VCEL)股价在11月11日盘中大涨5.03%,报收于56.72美元/股,引起市场广泛关注。
最新财报显示,尽管Vericel公司仍处于亏损状态,但营收和毛利表现不俗。公司专注于运动医学和严重烧伤护理领域,其两款细胞疗法产品MACI和Epicel拥有广阔的市场前景。
分析师对Vericel的发展前景持乐观态度。据了解,所有参与评级的7家机构全部给予该股买入评级,看好公司未来的增长潜力。此外,该公司所在的生物技术行业整体表现向好,也有利于公司股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.